Table 4. Overall, colorectal cancer disease-specific and disease-free survival by tumor subtype, HRs followed by CIs for Cox regression.
| Overall survival | Disease-specific survival | Disease-free survival | |||||
|---|---|---|---|---|---|---|---|
| Tumour subtype | N | HR (95 % CI) | P | HR (95 % CI) | P | HR (95 % CI) | P |
| MSS/BRAF-wild-type | 600 | 1 | 1 | 1 | |||
| MSI/BRAFV600E | 60 | 0.83 (0.54–1.27) | 0.386 | 0.58 (0.28–1.18) | 0.131 | 0.42 (0.18–0.96) | 0.039 |
| MSI/BRAF-wild-type | 44 | 1.16 (0.68–1.97) | 0.579 | 1.04 (0.48–2.25) | 0.93 | 0.86 (0.40–1.85) | 0.694 |
| MSS/BRAFV600E | 34 | 1.87 (1.17–3.00) | 0.009 | 1.88 (1.06–3.31) | 0.03 | 1.36 (0.59–3.15) | 0.468 |
Abbreviations: ASA=American Society of Anaesthesiologists; CI=confidence interval; HR=hazard ratio; MSI=microsatellite instability; MSS=microsatellite stable; UICC=Union for International Cancer Control.
Models were adjusted for age, sex, UICC stage, ASA class and operation type.
MSS/BRAF wild type is reference category.